Clomiphene Citrate

Overview

Clomiphene citrate is one of the oldest and most extensively studied selective estrogen receptor modulators (SERMs), first synthesized in 1956 and approved by the FDA in 1967 for the treatment of ovulatory dysfunction in women desiring pregnancy. Marketed under the brand names Clomid and Serophene, it has remained a first-line therapy for anovulatory infertility for over five decades, a testament to its efficacy, safety profile, and favorable cost-effectiveness ratio.

Clomiphene is a racemic mixture of two geometric isomers: enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene), present in an approximately 62:38 ratio in the commercial preparation. These isomers have distinct pharmacological properties: enclomiphene is primarily an estrogen receptor antagonist with a shorter half-life (approximately 10 hours), while zuclomiphene exhibits mixed agonist-antagonist activity with a substantially longer half-life (up to several weeks). The composite pharmacological effect of the racemic mixture reflects the combined actions of both isomers.

Beyond its established role in female infertility, clomiphene has been increasingly studied and used off-label for the treatment of male hypogonadism. By blocking estrogen-mediated negative feedback at the hypothalamic-pituitary level, clomiphene stimulates increased gonadotropin secretion, leading to enhanced testicular testosterone production while preserving spermatogenesis, a critical advantage over exogenous testosterone replacement therapy.

Mechanism of Action

Clomiphene exerts its primary therapeutic effect through competitive antagonism of estrogen receptors in the hypothalamus and anterior pituitary gland. By occupying estrogen receptors in these tissues, clomiphene prevents endogenous estradiol from exerting its normal negative feedback on gonadotropin-releasing hormone (GnRH) and gonadotropin secretion.

Hypothalamic-Pituitary Axis Stimulation

Under normal physiological conditions, circulating estradiol provides tonic negative feedback to hypothalamic GnRH-secreting neurons and pituitary gonadotrope cells, modulating the frequency and amplitude of GnRH pulses and the subsequent release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Clomiphene blocks this feedback loop by occupying hypothalamic estrogen receptors, effectively creating a state of perceived estrogen deficiency. The hypothalamus responds by increasing GnRH pulse frequency and amplitude, which in turn stimulates increased pituitary secretion of both LH and FSH.

Ovarian Stimulation in Women

The elevated FSH levels resulting from clomiphene’s hypothalamic blockade promote recruitment and maturation of ovarian follicles in anovulatory women. As follicles develop and produce increasing amounts of estradiol, the midcycle LH surge is triggered (either spontaneously or by the rising estradiol), leading to ovulation. The standard protocol involves administration of 50-150 mg daily for 5 days, beginning on cycle day 3 or 5, with ovulation typically occurring 5-12 days after the last dose.

Testosterone Stimulation in Men

In hypogonadal men, clomiphene’s blockade of hypothalamic estrogen feedback results in increased LH secretion, which stimulates Leydig cell testosterone production. Unlike exogenous testosterone, this mechanism preserves or even enhances intratesticular testosterone concentrations, maintaining the hormonal milieu necessary for ongoing spermatogenesis. Studies have demonstrated that clomiphene can raise serum testosterone levels by 100-200% from baseline in hypogonadal men while maintaining or improving sperm parameters.

Research Summary

Early Clinical Development

Greenblatt et al. (1961) published the foundational clinical study demonstrating clomiphene’s efficacy in inducing ovulation in anovulatory women. This landmark work, published in the Journal of the American Medical Association, established the basic clinical framework for clomiphene therapy that remains largely unchanged today. The study demonstrated ovulation rates of approximately 70-80% and pregnancy rates of 30-40% per treatment cycle in properly selected patients.

Male Hypogonadism Applications

Katz et al. (2012) published a comprehensive review in the BJU International evaluating clomiphene citrate for male hypogonadism and infertility. The analysis of available studies demonstrated that clomiphene therapy in hypogonadal men produced significant increases in serum testosterone (mean increases from approximately 250-350 ng/dL to 500-700 ng/dL), while maintaining or improving semen parameters. This contrasts sharply with exogenous testosterone therapy, which typically suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary-gonadal axis.

Comparative Efficacy and Safety

Multiple randomized controlled trials and meta-analyses have confirmed clomiphene’s position as the first-line pharmacological therapy for anovulatory infertility due to WHO Group II anovulation (including polycystic ovary syndrome). Overall ovulation rates range from 60-85%, with cumulative pregnancy rates of approximately 50-60% over 6 treatment cycles. The drug is generally well tolerated, with the most common side effects being hot flashes, visual disturbances, mood changes, and ovarian hyperstimulation. The risk of multiple gestation is approximately 5-8%, predominantly twins.

Dosing in Published Research

Clomiphene citrate is an FDA-approved prescription medicine, sold as Clomid. The FDA-approved labeling describes its use for ovulation induction in women:

• First cycle: 50 mg daily for 5 days.
• If ovulation does not occur: a subsequent course of 100 mg daily for 5 days may be used.
• Treatment is generally limited to about six cycles.

These figures are drawn from FDA-approved prescribing information. Use of clomiphene in men, for example for hypogonadism, is off-label and is not described by this labeling.

Safety and Side Effects

Clomiphene is an FDA-approved drug with a long-characterized safety profile. Common adverse effects include hot flashes, mood changes, headache, breast tenderness, and abdominal discomfort. A distinctive and clinically important effect is visual disturbance, including blurring, light sensitivity, floaters, or blind spots; these are usually reversible but warrant stopping the drug and seeking medical evaluation, as persistent visual changes have been reported. In its approved use for ovulation induction, clomiphene increases the chance of multiple pregnancy and can cause ovarian enlargement and, less commonly, ovarian hyperstimulation syndrome. It is contraindicated in pregnancy and in people with liver disease, abnormal uterine bleeding of undetermined cause, or hormone-sensitive tumors.

Current Research Status

Clomiphene citrate is an FDA-approved prescription medication, marketed as Clomid among other names, approved for ovulation induction in women with certain types of infertility. Its use in men, including for male hypogonadism or fertility, and its use alongside anabolic steroid cycles, are off-label and not part of the approved indication. As a prescription drug it should be used under medical supervision.

Further reading: Enclomiphene, the trans-isomer of clomiphene, is reviewed in Enclomiphene: The SERM Studied for Testosterone.

Frequently Asked Questions